guttitude logo

guttitude

early access
Get Checklistguttitude Pro
← Back to atlas
fulltoplow inflation risk

Roseburia

crohn's disease

Roseburia is an interesting but still moderate-confidence signal in crohn's disease.

Roseburia shows a strong literature footprint in crohn's disease, with substantial central evidence and broader supporting literature.

roseburia
Credibility score
58
Human translation
3/5
Reproducibility
4/5
Novelty
2/5
Actionability
4/5
Credibility 58Human translation 3/5Reproducibility 4/5Novelty 2/5Actionability 4/5
Why this scores the way it does
  • strong central evidence base
  • substantial preclinical support
Main caveats
  • directionality and confounding still require curated review

Primary central evidence

18 papers
A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.
2014
Gut
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Goji Berry Modulates Gut Microbiota and Alleviates Colitis in IL-10-Deficient Mice.
2018
Molecular nutrition & food research
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Characteristics of mucosa-associated gut microbiota during treatment in Crohn's disease.
2019
World journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut dysbiosis and clinical phases of pancolitis in patients with ulcerative colitis.
2021
MicrobiologyOpen
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Acupuncture improves the symptoms, intestinal microbiota, and inflammation of patients with mild to moderate Crohn's disease: A randomized controlled trial.
2022
EClinicalMedicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Features of the gut prokaryotic virome of Japanese patients with Crohn's disease.
2022
Journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Patients With Inflammatory Bowel Disease Show IgG Immune Responses Towards Specific Intestinal Bacterial Genera.
2022
Frontiers in immunology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota analysis for prediction of clinical relapse in Crohn's disease.
2022
Scientific reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota in the early stage of Crohn's disease has unique characteristics.
2022
Gut pathogens
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota signatures in inflammatory bowel disease.
2024
United European gastroenterology journal
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbiome and its relevance to indigenous inflammatory bowel diseases in China.
2024
Gene
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbial Disruptions in Inflammatory Bowel Disease: A Comparative Analysis.
2024
International journal of general medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Profiles and interactions of gut microbiome and intestinal microRNAs in pediatric Crohn's disease.
2024
mSystems
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Fecal microbiota transplantation restores gut microbiota diversity in children with active Crohn's disease: a prospective trial.
2025
Journal of translational medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Comprehensive analysis of faecal metagenomic and serum metabolism revealed the role of gut microbes and related metabolites in detecting colorectal lateral spreading tumours.
2025
Virulence
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
High-resolution analysis of the treated coeliac disease microbiome reveals strain-level variation.
2025
Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
The intestinal mucosa-associated microbiota in IBD-associated arthritis displays lower relative abundance of Roseburia intestinalis.
2025
Gut microbes
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gut microbiota-derived butyrate mediates the anticolitic effect of indigo supplementation through regulating CD4+ T cell differentiation.
2025
iMeta
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.

Supporting primary evidence

1 papers
Linkage analysis identifies novel genetic modifiers of microbiome traits in families with inflammatory bowel disease.
2022
Gut microbes
Human primary paper with plausible association relevance to the disease context.

Preclinical supporting evidence

12 papers
Diet rapidly and reproducibly alters the human gut microbiome.
2014
Nature
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Human Gut Symbiont Roseburia hominis Promotes and Regulates Innate Immunity.
2017
Frontiers in immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Insights into Roseburia intestinalis which alleviates experimental colitis pathology by inducing anti-inflammatory responses.
2018
Journal of gastroenterology and hepatology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Roseburia intestinalis inhibits interleukin‑17 excretion and promotes regulatory T cells differentiation in colitis.
2018
Molecular medicine reports
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Luteolin alleviates inflammation and modulates gut microbiota in ulcerative colitis rats.
2021
Life sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Roseburia intestinalis stimulates TLR5-dependent intestinal immunity against Crohn's disease.
2022
EBioMedicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut Microbiome Composition Is Associated With Future Onset of Crohn's Disease in Healthy First-Degree Relatives.
2023
Gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Faecalibacterium prausnitzii, Bacteroides faecis and Roseburia intestinalis attenuate clinical symptoms of experimental colitis by regulating Treg/Th17 cell balance and intestinal barrier integrity.
2023
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Roseburia intestinalis-derived extracellular vesicles ameliorate colitis by modulating intestinal barrier, microbiome, and inflammatory responses.
2024
Journal of extracellular vesicles
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Host-microbe interaction-mediated resistance to DSS-induced inflammatory enteritis in sheep.
2024
Microbiome
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Lactobacillus fermentum 016 Alleviates Mice Colitis by Modulating Oxidative Stress, Gut Microbiota, and Microbial Metabolism.
2025
Nutrients
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Metal-Organic Framework-Remodeled Gut Microbiota Alleviates Colonic Inflammation via Selective Modulation of Roseburia intestinalis.
2025
ACS nano
Disease-relevant preclinical or model-based paper useful as supporting evidence.

Review supporting evidence

10 papers
Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut.
2016
Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in Genus and Species.
2021
Frontiers in cellular and infection microbiology
Relevant review or meta-analysis for the signal-disease area.
Features of Gut Microbiome Associated With Responses to Fecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review.
2022
Frontiers in medicine
Relevant review or meta-analysis for the signal-disease area.
Alteration of the Gut Microbiome in Inflammatory Bowel Disease.
2023
Digestion
Relevant review or meta-analysis for the signal-disease area.
Anaerobes in specific infectious and noninfectious diseases: new developments.
2023
Anaerobe
Relevant review or meta-analysis for the signal-disease area.
Healing from Within: How Gut Microbiota Predicts IBD Treatment Success-A Systematic Review.
2024
International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota mediated T cells regulation and autoimmune diseases.
2024
Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Comparative analysis of Parkinson's and inflammatory bowel disease gut microbiomes reveals shared butyrate-producing bacteria depletion.
2025
NPJ Parkinson's disease
Relevant review or meta-analysis for the signal-disease area.
Is the microbiome the answer to inflammatory bowel disease: systematic review.
2025
Langenbeck's archives of surgery
Relevant review or meta-analysis for the signal-disease area.
The Structure-Decoding-Conversion-Effect Paradigm of Natural Polysaccharides for Gut Microbiota Remodeling in Ulcerative Colitis.
2026
Nutrients
Relevant review or meta-analysis for the signal-disease area.